2. Academic Validation
  3. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells

Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells

  • Nat Cell Biol. 2015 Aug;17(8):994-1003. doi: 10.1038/ncb3205.
Christoph Patsch 1,  Ludivine Challet-Meylan 2,  Eva C Thoma 1,  Eduard Urich 1,  Tobias Heckel 1,  John F O'Sullivan 3,  Stephanie J Grainger 4,  Friedrich G Kapp 5,  Lin Sun 3,  Klaus Christensen 1,  Yulei Xia 2,  Mary H C Florido 2,  Wei He 1,  Wei Pan 1,  Michael Prummer 1,  Curtis R Warren 2,  Roland Jakob-Roetne 1,  Ulrich Certa 1,  Ravi Jagasia 1,  Per-Ola Freskgård 1,  Isaac Adatto 3,  Dorothee Kling 1,  Paul Huang 3,  Leonard I Zon 6,  Elliot L Chaikof 4,  Robert E Gerszten 3,  Martin Graf 1,  Roberto Iacone 1,  Chad A Cowan 7
Affiliations

Affiliations

  • 1 Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
  • 2 Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, Massachusetts 02138, USA.
  • 3 Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
  • 4 1] Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F Boston, Massachusetts 02115, USA [2] The Wyss Institute of Biologically Inspired Engineering of Harvard University, Boston, Massachusetts 02115, USA.
  • 5 Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 6 1] Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, Massachusetts 02138, USA [2] Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 7 1] Department of Stem Cell and Regenerative Biology and Harvard Stem Cell Institute, Harvard University, Massachusetts 02138, USA [2] Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA [3] Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
PMID: 26214132 DOI: 10.1038/ncb3205
Abstract

The use of human pluripotent stem cells for in vitro disease modelling and clinical applications requires protocols that convert these cells into relevant adult cell types. Here, we report the rapid and efficient differentiation of human pluripotent stem cells into vascular endothelial and smooth muscle cells. We found that GSK3 inhibition and BMP4 treatment rapidly committed pluripotent cells to a mesodermal fate and subsequent exposure to VEGF-A or PDGF-BB resulted in the differentiation of either endothelial or vascular smooth muscle cells, respectively. Both protocols produced mature cells with efficiencies exceeding 80% within six days. On purification to 99% via surface markers, endothelial cells maintained their identity, as assessed by marker gene expression, and showed relevant in vitro and in vivo functionality. Global transcriptional and metabolomic analyses confirmed that the cells closely resembled their in vivo counterparts. Our results suggest that these cells could be used to faithfully model human disease.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100207
    99.63%, GSK-3β Inhibitor